BIIB Jan 2025 215.000 put
| Previous close | 18.30 |
| Open | 19.00 |
| Bid | 16.70 |
| Ask | 21.60 |
| Strike | 215.00 |
| Expiry date | 2025-01-17 |
| Day's range | 18.90 - 19.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 121 |
Investor's Business DailyIs Eli Lilly Stock A Buy After Weight-Loss Drug Prevents Diabetes?
Is Eli Lilly stock a buy after the company said its weight-loss drug reduced the risk of developing diabetes by 94%?
ZacksWhy Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR NewswireLeqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the humanized amyloid-beta (Aβ) monoclonal antibody "Leqembi®" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatment of mild cognitive imp
